Depreciation of Aclaris Therapeutics, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Aclaris Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Aclaris Therapeutics, Inc. Depreciation for the quarter ending 30 Sep 2025 was $100,000, a 50% decline year-over-year.
  • Aclaris Therapeutics, Inc. Depreciation for the twelve months ending 30 Sep 2025 was $400,000, a 50% decline year-over-year.
  • Aclaris Therapeutics, Inc. annual Depreciation for 2024 was $700,000, a 12% decline from 2023.
  • Aclaris Therapeutics, Inc. annual Depreciation for 2023 was $800,000, a 14% increase from 2022.
  • Aclaris Therapeutics, Inc. annual Depreciation for 2022 was $700,000, a 12% decline from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Aclaris Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $400,000 $100,000 -$100,000 -50% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $500,000 $100,000 -$100,000 -50% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $600,000 $100,000 -$100,000 -50% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $700,000 $100,000 -$100,000 -50% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $800,000 $200,000 $0 0% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $800,000 $200,000 $0 0% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $800,000 $200,000 $0 0% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $800,000 $200,000 +$100,000 +100% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $700,000 $200,000 $0 0% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $700,000 $200,000 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $700,000 $200,000 $0 0% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $700,000 $100,000 -$100,000 -50% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $800,000 $200,000 $0 0% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $800,000 $200,000 $0 0% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $800,000 $200,000 $0 0% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $800,000 $200,000 $0 0% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $800,000 $200,000 -$100,000 -33% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $900,000 $200,000 -$100,000 -33% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $1,000,000 $200,000 -$100,000 -33% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $1,100,000 $200,000 -$205,000 -51% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $1,305,000 $300,000 $0 0% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $1,305,000 $300,000 -$93,000 -24% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $1,398,000 $300,000 -$102,000 -25% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $1,500,000 $405,000 -$32,000 -7.3% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $1,532,000 $300,000 +$36,000 +14% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $1,496,000 $393,000 +$97,000 +33% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $1,399,000 $402,000 +$199,000 +98% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $1,200,000 $437,000 +$275,000 +170% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $925,000 $264,000 +$161,000 +156% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $764,000 $296,000 +$241,000 +438% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $523,000 $203,000 +$153,000 +306% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $370,000 $162,000 +$122,000 +305% 01 Oct 2017 31 Dec 2017 10-K 25 Feb 2020 2019 FY
Q3 2017 $248,000 $103,000 +$71,000 +222% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $177,000 $55,000 +$28,000 +104% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $149,000 $50,000 +$29,000 +138% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $120,000 $40,000 +$7,000 +21% 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $113,000 $32,000 $0 0% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $113,000 $27,000 +$5,000 +23% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $108,000 $21,000 +$18,000 +600% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $90,000 $33,000 01 Oct 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
Q3 2015 $32,000 +$29,000 +967% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $22,000 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $3,000 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1
Q3 2014 $3,000 01 Jul 2014 30 Sep 2014 10-Q 03 Dec 2015 2015 Q3

Aclaris Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $700,000 -$100,000 -12% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $800,000 +$100,000 +14% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $700,000 -$100,000 -12% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $800,000 -$300,000 -27% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $1,100,000 -$400,000 -27% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $1,500,000 +$300,000 +25% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $1,200,000 +$830,000 +224% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $370,000 +$250,000 +208% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2020 2019 FY
2016 $120,000 +$30,000 +33% 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
2015 $90,000 +$78,000 +650% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $12,000 +$1,000 +9.1% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
2013 $11,000 01 Jan 2013 31 Dec 2013 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.